alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with Alzheimer Disease in 29 studies
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Furthermore, in Alzheimer's disease we hypothesized that cells at risk for developing AD neuropathology will express certain combinations of glutamate receptor subunits that form channels with increased permeability to Ca2+." | 2.47 | Age- and disease-related neuroplasticity of chemically identified neuronal circuits: a tribute to Professor Erminio Costa. ( Armstrong, D, 2011) |
| "Key pathological features of Alzheimer's disease (AD) include build-up of amyloid β (Aβ), which promotes synaptic abnormalities and ultimately leads to neuronal cell death." | 1.91 | Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration. ( Ainge, JA; Doherty, G; Duncan, S; Flewitt, I; Hamilton, K; Harvey, J; Holiday, A; MacLeod, B; Malekizadeh, Y; Manolescu, C, 2023) |
| "As a neurodegenerative disease, Alzheimer's disease (AD) seriously affects the health of older people." | 1.72 | A Class I HDAC Inhibitor Rescues Synaptic Damage and Neuron Loss in APP-Transfected Cells and APP/PS1 Mice through the GRIP1/AMPA Pathway. ( Chen, J; Chen, L; Chu, H; Guo, Y; Han, Y; Liu, J; Ma, H; Wang, C; Yu, X; Zhang, C, 2022) |
| "In 2-month-old mice, no β-amyloid plaques deposition, but the presence of soluble oligomers, were found in CA1 area but not in dentate gyrus (DG)." | 1.42 | Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. ( Borsello, T; Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Ghiglieri, V; Sclip, A; Tantucci, M; Tozzi, A, 2015) |
| "Cognitive decline in Alzheimer's disease (AD) stems from the progressive dysfunction of synaptic connections within cortical neuronal microcircuits." | 1.33 | Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. ( Burnashev, N; Farkas, T; Fülöp, L; Harkany, T; Härtig, W; Holmgren, C; Min, R; Penke, B; Shemer, I; Sousa, KM; Tanila, H; Zilberter, M; Zilberter, Y, 2006) |
| "Since Alzheimer's disease is known to be associated with down-regulation of the cholinergic and N-methyl-D-aspartate (NMDA) systems, most of these drugs inhibit acetylcholinesterase, potentiate the activity of nicotinic acetylcholine receptors (nAChRs), or modulate NMDA receptors." | 1.33 | In vitro galantamine-memantine co-application: mechanism of beneficial action. ( Huang, J; Marszalec, W; Narahashi, T; Toth, PT; Yeh, JZ; Zhao, X, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (31.03) | 18.2507 |
| 2000's | 5 (17.24) | 29.6817 |
| 2010's | 8 (27.59) | 24.3611 |
| 2020's | 7 (24.14) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, C | 1 |
| Wen, D | 1 |
| Zhang, Y | 1 |
| Mustaklem, R | 1 |
| Mustaklem, B | 1 |
| Zhou, M | 1 |
| Ma, T | 1 |
| Ma, YY | 1 |
| Han, Y | 1 |
| Chen, L | 1 |
| Liu, J | 1 |
| Chen, J | 1 |
| Wang, C | 1 |
| Guo, Y | 1 |
| Yu, X | 1 |
| Zhang, C | 1 |
| Chu, H | 1 |
| Ma, H | 1 |
| Doherty, G | 3 |
| Holiday, A | 3 |
| Malekizadeh, Y | 3 |
| Manolescu, C | 3 |
| Duncan, S | 3 |
| Flewitt, I | 3 |
| Hamilton, K | 3 |
| MacLeod, B | 3 |
| Ainge, JA | 3 |
| Harvey, J | 3 |
| Lilek, J | 1 |
| Ajroud, K | 1 |
| Feldman, AZ | 1 |
| Krishnamachari, S | 1 |
| Ghourchian, S | 1 |
| Gefen, T | 1 |
| Spencer, CL | 1 |
| Kawles, A | 1 |
| Mao, Q | 1 |
| Tranovich, JF | 1 |
| Jack, CR | 1 |
| Mesulam, MM | 1 |
| Reichard, RR | 1 |
| Zhang, H | 1 |
| Murray, ME | 1 |
| Knopman, D | 1 |
| Dickson, DW | 1 |
| Petersen, RC | 1 |
| Smith, B | 1 |
| Ashe, KH | 1 |
| Mielke, MM | 1 |
| Nelson, KM | 1 |
| Flanagan, ME | 1 |
| Abghari, M | 1 |
| Vu, JTCM | 1 |
| Eckberg, N | 1 |
| Aldana, BI | 1 |
| Kohlmeier, KA | 1 |
| Fernández-Pérez, EJ | 1 |
| Gallegos, S | 1 |
| Armijo-Weingart, L | 1 |
| Araya, A | 1 |
| Riffo-Lepe, NO | 1 |
| Cayuman, F | 1 |
| Aguayo, LG | 1 |
| Fani, G | 1 |
| Mannini, B | 1 |
| Vecchi, G | 1 |
| Cascella, R | 1 |
| Cecchi, C | 1 |
| Dobson, CM | 1 |
| Vendruscolo, M | 1 |
| Chiti, F | 1 |
| Bretin, S | 1 |
| Krazem, A | 1 |
| Henkous, N | 1 |
| Froger-Colleaux, C | 1 |
| Mocaer, E | 1 |
| Louis, C | 1 |
| Perdaems, N | 1 |
| Marighetto, A | 1 |
| Beracochea, D | 1 |
| Hettinger, JC | 1 |
| Lee, H | 1 |
| Bu, G | 1 |
| Holtzman, DM | 1 |
| Cirrito, JR | 1 |
| Baglietto-Vargas, D | 1 |
| Prieto, GA | 1 |
| Limon, A | 1 |
| Forner, S | 1 |
| Rodriguez-Ortiz, CJ | 1 |
| Ikemura, K | 1 |
| Ager, RR | 1 |
| Medeiros, R | 1 |
| Trujillo-Estrada, L | 1 |
| Martini, AC | 1 |
| Kitazawa, M | 1 |
| Davila, JC | 1 |
| Cotman, CW | 1 |
| Gutierrez, A | 1 |
| LaFerla, FM | 1 |
| Gong, B | 1 |
| Pan, Y | 1 |
| Zhao, W | 1 |
| Knable, L | 1 |
| Vempati, P | 1 |
| Begum, S | 1 |
| Ho, L | 1 |
| Wang, J | 1 |
| Yemul, S | 1 |
| Barnum, S | 1 |
| Bilski, A | 1 |
| Gong, BY | 1 |
| Pasinetti, GM | 1 |
| Wang, Y | 1 |
| Mattson, MP | 1 |
| Tozzi, A | 1 |
| Sclip, A | 1 |
| Tantucci, M | 1 |
| de Iure, A | 1 |
| Ghiglieri, V | 1 |
| Costa, C | 1 |
| Di Filippo, M | 1 |
| Borsello, T | 1 |
| Calabresi, P | 1 |
| Armstrong, D | 1 |
| Vellas, B | 1 |
| Pesce, A | 1 |
| Robert, PH | 1 |
| Aisen, PS | 1 |
| Ancoli-Israel, S | 1 |
| Andrieu, S | 1 |
| Cedarbaum, J | 1 |
| Dubois, B | 1 |
| Siemers, E | 1 |
| Spire, JP | 1 |
| Weiner, MW | 1 |
| May, TS | 1 |
| Louzada, PR | 1 |
| Paula Lima, AC | 1 |
| Mendonca-Silva, DL | 1 |
| Noël, F | 1 |
| De Mello, FG | 1 |
| Ferreira, ST | 1 |
| Shemer, I | 1 |
| Holmgren, C | 1 |
| Min, R | 1 |
| Fülöp, L | 1 |
| Zilberter, M | 1 |
| Sousa, KM | 1 |
| Farkas, T | 1 |
| Härtig, W | 1 |
| Penke, B | 1 |
| Burnashev, N | 1 |
| Tanila, H | 1 |
| Zilberter, Y | 1 |
| Harkany, T | 1 |
| Zhao, X | 1 |
| Marszalec, W | 1 |
| Toth, PT | 1 |
| Huang, J | 1 |
| Yeh, JZ | 1 |
| Narahashi, T | 1 |
| Bowen, DM | 1 |
| Procter, AW | 1 |
| Mann, DM | 1 |
| Snowden, JS | 1 |
| Esiri, MM | 1 |
| Neary, D | 1 |
| Francis, PT | 1 |
| Muir, JL | 1 |
| Page, KJ | 1 |
| Sirinathsinghji, DJ | 1 |
| Robbins, TW | 1 |
| Everitt, BJ | 1 |
| Weiss, JH | 1 |
| Yin, HZ | 1 |
| Choi, DW | 1 |
| Yasuda, RP | 1 |
| Ikonomovic, MD | 1 |
| Sheffield, R | 1 |
| Rubin, RT | 1 |
| Wolfe, BB | 1 |
| Armstrong, DM | 1 |
| Krogsgaard-Larsen, P | 1 |
| Wahl, P | 1 |
| Schousboe, A | 1 |
| Madsen, U | 1 |
| Hansen, JJ | 1 |
| Vickers, JC | 1 |
| Huntley, GW | 1 |
| Edwards, AM | 1 |
| Moran, T | 1 |
| Rogers, SW | 1 |
| Heinemann, SF | 1 |
| Morrison, JH | 1 |
| Ulus, IH | 1 |
| Wurtman, RJ | 1 |
| Zhang, JM | 1 |
| Hu, GY | 1 |
| Dewar, D | 3 |
| Chalmers, DT | 3 |
| Graham, DI | 3 |
| McCulloch, J | 3 |
| Shand, A | 1 |
| Brooks, DN | 1 |
3 reviews available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Alzheimer Disease
| Article | Year |
|---|---|
Age- and disease-related neuroplasticity of chemically identified neuronal circuits: a tribute to Professor Erminio Costa.
Topics: Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; A | 2011 |
Excitotoxic lesions of basal forebrain cholinergic neurons: effects on learning, memory and attention.
Topics: Acetylcholine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; | 1993 |
Excitatory amino acid research in Alzheimer's disease: enhancement and blockade of receptor functions.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Humans; Iboten | 1993 |
26 other studies available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and Alzheimer Disease
| Article | Year |
|---|---|
Amyloid-β oligomers in the nucleus accumbens decrease motivation via insertion of calcium-permeable AMPA receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2022 |
A Class I HDAC Inhibitor Rescues Synaptic Damage and Neuron Loss in APP-Transfected Cells and APP/PS1 Mice through the GRIP1/AMPA Pathway.
Topics: Adaptor Proteins, Signal Transducing; Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 2022 |
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Leptin-based hexamers facilitate memory and prevent amyloid-driven AMPA receptor internalisation and neuronal degeneration.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer's Disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Brain; Cognitive Dysfun | 2023 |
Decanoic Acid Rescues Differences in AMPA-Mediated Calcium Rises in Hippocampal CA1 Astrocytes and Neurons in the 5xFAD Mouse Model of Alzheimer's Disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2023 |
Changes in neuronal excitability and synaptic transmission in nucleus accumbens in a transgenic Alzheimer's disease mouse model.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Biomarkers; Di | 2020 |
Aβ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2021 |
Synergistic enhancing-memory effect of donepezil and S 47445, an AMPA positive allosteric modulator, in middle-aged and aged mice.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Benzoxazines; | 2018 |
AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Peptides; | 2018 |
Impaired AMPA signaling and cytoskeletal alterations induce early synaptic dysfunction in a mouse model of Alzheimer's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Cytoskeleton; | 2018 |
IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Protein Pr | 2013 |
L-type Ca2+ currents at CA1 synapses, but not CA3 or dentate granule neuron synapses, are increased in 3xTgAD mice in an age-dependent manner.
Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Pep | 2014 |
Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease.
Topics: Aging; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Pro | 2015 |
AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Cholinesterase Inhibito | 2011 |
Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Protein Pr | 2004 |
Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
Topics: Action Potentials; Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer | 2006 |
In vitro galantamine-memantine co-application: mechanism of beneficial action.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolep | 2006 |
Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.
Topics: Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Choline O-Acetylt | 2008 |
Basal forebrain cholinergic neurons are selectively vulnerable to AMPA/kainate receptor-mediated neurotoxicity.
Topics: Acetylcholine; Acetylcholinesterase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzhe | 1994 |
Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study.
Topics: Aged; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Blotting, Western | 1995 |
Quantitative localization of AMPA/kainate and kainate glutamate receptor subunit immunoreactivity in neurochemically identified subpopulations of neurons in the prefrontal cortex of the macaque monkey.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Antibodies; Bi | 1993 |
Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Protein Pr | 1997 |
Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons.
Topics: Alkaloids; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Cel | 2001 |
Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus.
Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease | 1991 |
Selective reduction of quisqualate (AMPA) receptors in Alzheimer cerebellum.
Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease | 1990 |
Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.
Topics: Aged; Aged, 80 and over; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease | 1990 |